Pro­tag­o­nist un­veils 'triple-G' obe­si­ty pill, but hu­man tri­als are near­ly a year away

Pro­tag­o­nist Ther­a­peu­tics is a late en­trant in­to the obe­si­ty space, but it can­not be ac­cused of fol­low­ing the crowd.

The Cal­i­for­nia-based biotech un­veiled its on­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER